Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Crohn's disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    413 result(s) found for: Crohn's disease. Displaying page 2 of 21.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006957-42 Sponsor Protocol Number: BUG-2/CDA Start Date*: 2009-10-30
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide th...
    Medical condition: Induction of remission in active Crohn´s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10058815 Crohn's disease acute episode LLT
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LT (Completed) BG (Completed) CZ (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-003365-38 Sponsor Protocol Number: VTX958-202 Start Date*: 2023-03-31
    Sponsor Name:Ventyx Biosciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s D...
    Medical condition: Moderately to severely active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LT (Completed) DE (Prematurely Ended) HU (Prematurely Ended) IT (Completed) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002763-34 Sponsor Protocol Number: GS-US-419-3896 Start Date*: 2017-02-08
    Sponsor Name:Galapagos NV
    Full Title: A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IS (Completed) SE (Completed) GR (Completed) PT (Completed) SK (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) NL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005966-39 Sponsor Protocol Number: TJT1123 Start Date*: 2012-03-08
    Sponsor Name:CHU-ULg
    Full Title: Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders.
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011402 Crohn's disease (colon) LLT
    14.0 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    14.0 10017947 - Gastrointestinal disorders 10064147 Gastrointestinal inflammation PT
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001278-13 Sponsor Protocol Number: PROSIBD Start Date*: 2016-06-08
    Sponsor Name:Taina Sipponen
    Full Title: Immunologic, genetic and microbiomic predictors of the treatment response for TNFalpha-blocking drugs – prospective follow-up cohort of patients with Crohn’s disease or ulcerative colitis
    Medical condition: Ulcerative colitis and Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    19.0 10017947 - Gastrointestinal disorders 10013099 Disease Crohns LLT
    19.0 10017947 - Gastrointestinal disorders 10058815 Crohn's disease acute episode LLT
    19.0 10017947 - Gastrointestinal disorders 10057035 Crohn's ileocolitis LLT
    19.0 10017947 - Gastrointestinal disorders 10011405 Crohn's enteritis LLT
    19.0 10017947 - Gastrointestinal disorders 10011406 Crohn's ileitis LLT
    19.0 10017947 - Gastrointestinal disorders 10076318 Crohn's disease relapse LLT
    19.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    19.0 10017947 - Gastrointestinal disorders 10011402 Crohn's disease (colon) LLT
    19.0 10017947 - Gastrointestinal disorders 10075466 Fistulising Crohn's disease LLT
    19.0 10017947 - Gastrointestinal disorders 10066678 Acute ulcerative colitis LLT
    19.0 10017947 - Gastrointestinal disorders 10075465 Fistulizing Crohn's disease LLT
    19.0 10017947 - Gastrointestinal disorders 10011400 Crohn's colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004276-49 Sponsor Protocol Number: CD-LAQ-201 Start Date*: 2008-09-16
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: Estudio de fase IIa, multicéntrico, randomizado, doble ciego, controlado con placebo, de cohortes secuenciales, de búsqueda de rango de dosis para evaluar la seguridad, tolerabilidad y el efecto cl...
    Medical condition: Enfermedad de Crohn activa de moderada a grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001913-41 Sponsor Protocol Number: C87085 Start Date*: 2007-12-12
    Sponsor Name:UCB Celltech
    Full Title: A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha mono...
    Medical condition: Crohn`s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) HU (Completed) LV (Completed) BE (Completed) EE (Completed) IT (Completed) DE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001729-24 Sponsor Protocol Number: C87046 Start Date*: 2006-10-18
    Sponsor Name:UCB S.A.
    Full Title: Open label long term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy with certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF) in...
    Medical condition: Patients with Crohn's disease and having completed C87042 study.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004814-41 Sponsor Protocol Number: M06-806 Start Date*: 2007-08-07
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Di...
    Medical condition: Moderate to Severe Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) BE (Completed) NL (Completed) GB (Completed) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003977-25 Sponsor Protocol Number: C87043 Start Date*: 2007-01-31
    Sponsor Name:UCB S.A
    Full Title: A phase III B multicentre open label 54 weeks clinical trial evaluating certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF alpha) on endoscopic a...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002078-23 Sponsor Protocol Number: M06-829 Start Date*: 2006-10-12
    Sponsor Name:Abbott GmbH & Co. KG (Abbott)
    Full Title: A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease.
    Medical condition: Moderate to severe Crohn's Disease (Harvey Bradshaw Index score greater or equal to7).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) NO (Completed) FI (Completed) PT (Completed) SK (Completed) DE (Completed) IE (Completed) DK (Completed) FR (Completed) AT (Completed) GB (Completed) SE (Completed) GR (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002432-93 Sponsor Protocol Number: NN8828-4004 Start Date*: 2013-01-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn’s disease
    Medical condition: Crohns disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005770-99 Sponsor Protocol Number: 1368-0059 Start Date*: 2021-09-24
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn’s Disease
    Medical condition: Fibrostenotic Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NO (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022760-12 Sponsor Protocol Number: CNTO1275CRD3003 Start Date*: 2011-09-13
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Seve...
    Medical condition: Moderately to severely active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) BE (Completed) CZ (Completed) IS (Completed) IE (Completed) FR (Completed) HU (Completed) NL (Completed) DK (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002693-37 Sponsor Protocol Number: CD-2 Start Date*: 2004-12-10
    Sponsor Name:Therakos
    Full Title: A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPP...
    Medical condition: Patients with Moderately Active Crohn’s Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents
    Disease: Version SOC Term Classification Code Term Level
    7.1 10011401 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005526-23 Sponsor Protocol Number: NSP/0002/07 Start Date*: 2009-01-29
    Sponsor Name:Provexis Plc
    Full Title: Randomised controlled trial of soluble plantain fibre for maintenance of health during periods of remission in Crohn's disease v2
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002389-33 Sponsor Protocol Number: CNTO1959CRD3007 Start Date*: 2023-04-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection
    Medical condition: Crohn’s Disease After Surgical Resection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000189-19 Sponsor Protocol Number: DSC/06/2357/23 Start Date*: 2007-08-06
    Sponsor Name:Italfarmaco S.p.A.
    Full Title: Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease
    Medical condition: Moderate-to-severe active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004399-42 Sponsor Protocol Number: C87037 Start Date*: 2015-03-05
    Sponsor Name:UCB Japan Co., Ltd.
    Full Title: A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With...
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020836-21 Sponsor Protocol Number: NN8555-3797 Start Date*: 2011-01-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’...
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 07 17:22:29 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA